{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-006755","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.868212+00:00","generated_at":"2026-06-27T04:54:45.555353+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbCellera FY2021 revenue $375M (+61% YoY); EPS $0.56; 26 new program starts","bullets":["Total revenue $375.2M (up 61% from $233.2M in 2020), driven by $327.3M in royalty revenue.","Net earnings $153.5M ($0.56 basic EPS) vs. $118.9M ($0.53) in 2020; diluted EPS $0.48.","Ended year with $723M in cash and marketable securities; 26 new program starts (78 cumulative).","Q4 revenue $139.3M (37% of FY total), net earnings $59.9M ($0.21 basic EPS).","Five molecules now in clinic (up from one); acquired TetraGenetics for transmembrane protein targets."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-006755","json":"https://secwatch.observer/filing/0001564590-22-006755.json","markdown":"https://secwatch.observer/filing/0001564590-22-006755.md","text":"https://secwatch.observer/filing/0001564590-22-006755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022006755/0001564590-22-006755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022006755/abcl-8k_20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:54:45.555353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}